These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35318890)

  • 1. Screening of indole derivatives as the potent anticancer agents on dihydrofolate reductase: pharmaco-informatics and molecular dynamics simulation.
    Abdolmaleki B; Maddah M
    J Biomol Struct Dyn; 2023 May; 41(8):3667-3679. PubMed ID: 35318890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phthalide derivatives as dihydrofolate reductase inhibitors for malaria: molecular docking and molecular dynamics studies.
    Ibraheem W; Makki AA; Alzain AA
    J Biomol Struct Dyn; 2023 Jul; 41(11):5127-5137. PubMed ID: 35635144
    [No Abstract]   [Full Text] [Related]  

  • 3. Identification of Selective Inhibitors of
    Sharma VK; Bharatam PV
    J Comput Biol; 2021 Jan; 28(1):43-59. PubMed ID: 32207987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico screening of inhibitors against human dihydrofolate reductase to identify potential anticancer compounds.
    Soofi A; Rezaei-Tavirani M; Safari-Alighiarloo N
    J Biomol Struct Dyn; 2023; 41(23):14497-14509. PubMed ID: 36883866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Silico Study Identified Methotrexate Analog as Potential Inhibitor of Drug Resistant Human Dihydrofolate Reductase for Cancer Therapeutics.
    Rana RM; Rampogu S; Abid NB; Zeb A; Parate S; Lee G; Yoon S; Kim Y; Kim D; Lee KW
    Molecules; 2020 Jul; 25(15):. PubMed ID: 32752079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism inspired development of rationally designed dihydrofolate reductase inhibitors as anticancer agents.
    Singh P; Kaur M; Sachdeva S
    J Med Chem; 2012 Jul; 55(14):6381-90. PubMed ID: 22734697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phytochemical constituents of
    Jose S; Devi SS; P S; Al-Khafaji K
    J Biomol Struct Dyn; 2022; 40(22):11932-11947. PubMed ID: 34424817
    [No Abstract]   [Full Text] [Related]  

  • 8. Virtual screening, docking, and dynamics of potential new inhibitors of dihydrofolate reductase from Yersinia pestis.
    Bastos Lda C; de Souza FR; Guimarães AP; Sirouspour M; Cuya Guizado TR; Forgione P; Ramalho TC; França TC
    J Biomol Struct Dyn; 2016 Oct; 34(10):2184-98. PubMed ID: 26494420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular docking, 3D-QSAR and simulation studies for identifying pharmacophoric features of indole derivatives as 17β-hydroxysteroid dehydrogenase type 5 (17β-HSD5) inhibitors.
    Kulkarni S; Singh Y; Biharee A; Bhatia N; Monga V; Thareja S
    J Biomol Struct Dyn; 2023; 41(22):12668-12685. PubMed ID: 36744535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of selective
    Sharma VK; Kathuria D; Bharatam PV
    J Biomol Struct Dyn; 2022; 40(19):8687-8695. PubMed ID: 33904374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Halogenated derivatives of methotrexate as human dihydrofolate reductase inhibitors in cancer chemotherapy.
    Uddin N; Ahmed S; Khan AM; Mazharol Hoque M; Halim MA
    J Biomol Struct Dyn; 2020 Feb; 38(3):901-917. PubMed ID: 30938661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and validation of potent inhibitor of
    Sharma S; Tyagi R; Srivastava M; Rani K; Kumar D; Asthana S; Raj VS
    J Biomol Struct Dyn; 2023 Jul; 41(11):5117-5126. PubMed ID: 35652895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applying the designed multiple ligands approach to inhibit dihydrofolate reductase and thioredoxin reductase for anti-proliferative activity.
    Ng HL; Chen S; Chew EH; Chui WK
    Eur J Med Chem; 2016 Jun; 115():63-74. PubMed ID: 26994844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unveiling the Efficacy of Sesquiterpenes from Marine Sponge
    Omar AM; Mohammad KA; Sindi IA; Mohamed GA; Ibrahim SRM
    Molecules; 2023 Jan; 28(3):. PubMed ID: 36770958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DHFR Inhibitors: Reading the Past for Discovering Novel Anticancer Agents.
    Raimondi MV; Randazzo O; La Franca M; Barone G; Vignoni E; Rossi D; Collina S
    Molecules; 2019 Mar; 24(6):. PubMed ID: 30909399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicomplex-based pharmacophore modeling in conjunction with multi-target docking and molecular dynamics simulations for the identification of
    Manhas A; Lone MY; Jha PC
    J Biomol Struct Dyn; 2019 Oct; 37(16):4181-4199. PubMed ID: 30648473
    [No Abstract]   [Full Text] [Related]  

  • 17. Developing Hispolon-based novel anticancer therapeutics against human (NF-κβ) using
    Paul M; Kumar Panda M; Thatoi H
    J Biomol Struct Dyn; 2019 Sep; 37(15):3947-3967. PubMed ID: 30295165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probing the structure of Leishmania major DHFR TS and structure based virtual screening of peptide library for the identification of anti-leishmanial leads.
    Rajasekaran R; Chen YP
    J Mol Model; 2012 Sep; 18(9):4089-100. PubMed ID: 22527276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New small-molecule inhibitors of dihydrofolate reductase inhibit Streptococcus mutans.
    Zhang Q; Nguyen T; McMichael M; Velu SE; Zou J; Zhou X; Wu H
    Int J Antimicrob Agents; 2015 Aug; 46(2):174-82. PubMed ID: 26022931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homology modelling, molecular docking, and molecular dynamics simulations reveal the inhibition of Leishmania donovani dihydrofolate reductase-thymidylate synthase enzyme by Withaferin-A.
    Vadloori B; Sharath AK; Prabhu NP; Maurya R
    BMC Res Notes; 2018 Apr; 11(1):246. PubMed ID: 29661206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.